(Q47867265)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Cataplexy--clinical aspects, pathophysiology and management strategy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Regis Lopez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Jerry M Siegel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Zoltan A Torontali

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

John H Peever

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

language of work or name

English

0 references

publication date

3 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

386-395

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24890646%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrneurol.2014.97

19 March 2020

exact match

0 references

cites work

Narcolepsy with cataplexy

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Clinical aspects and pathophysiology of narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Age at onset of narcolepsy in two large populations of patients in France and Quebec.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

A noradrenergic mechanism functions to couple motor behavior with arousal state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Functional implications of sleep development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Reduced number of hypocretin neurons in human narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

ImmunoChip study implicates antigen presentation to T cells in narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Narcolepsy is strongly associated with the T-cell receptor alpha locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Common variants in P2RY11 are associated with narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

The clinical features of cataplexy: A questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

21 January 2018

Narcolepsy and cataplexy

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

The clinical spectrum of narcolepsy with cataplexy: a reappraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Behavioural and neurophysiological correlates of human cataplexy: a video-polygraphic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Complex movement disorders at disease onset in childhood narcolepsy with cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Clinical and polysomnographic course of childhood narcolepsy with cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Amygdala lesions reduce cataplexy in orexin knock-out mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Narcolepsy and the hypocretin system--where motion meets emotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Humor as a reward mechanism: event-related potentials in the healthy and diseased brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Anomalous hypothalamic responses to humor in cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Abnormal activity in reward brain circuits in human narcolepsy with cataplexy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Cerebral perfusion changes during cataplexy in narcolepsy patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

A brain PET study in patients with narcolepsy-cataplexy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Narcolepsy: a key role for hypocretins (orexins)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Electroencephalogram paroxysmal θ characterizes cataplexy in mice and children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Feeding-elicited cataplexy in orexin knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Identification of the transmitter and receptor mechanisms responsible for REM sleep paralysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Locus coeruleus neurons: cessation of activity during cataplexy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Orexin neurons suppress narcolepsy via 2 distinct efferent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Behavioral correlates of activity in identified hypocretin/orexin neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Orexin/hypocretin system and autonomic control: new insights and clinical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Greatly increased numbers of histamine cells in human narcolepsy with cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Increase of histaminergic tuberomammillary neurons in narcolepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Abnormal activity in hypothalamus and amygdala during humour processing in human narcolepsy with cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

A putative flip-flop switch for control of REM sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Hypocretin-2 saporin lesions of the ventrolateral periaquaductal gray (vlPAG) increase REM sleep in hypocretin knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Pharmacological aspects of human and canine narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

EFNS guidelines on management of narcolepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Gamma-hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABA(B) receptor-mediated effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

[The neurophysiology of cataplexy]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Changes in inhibitory amino acid release linked to pontine-induced atonia: an in vivo microdialysis study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Medullary regions mediating atonia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Activation of pontine and medullary motor inhibitory regions reduces discharge in neurons located in the locus coeruleus and the anatomical equivalent of the midbrain locomotor region.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Neurons containing hypocretin (orexin) project to multiple neuronal systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Activity of medial mesopontine units during cataplexy and sleep-waking states in the narcoleptic dog

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Clomipramine and clonazepam in cataplexy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Atomoxetine also effective in patients suffering from narcolepsy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.97

Sodium oxybate: updates and correction to previously published safety data

31 March 2020

1 reference

12 December 2020

Narcolepsy with cataplexy associated with holoprosencephaly misdiagnosed as epileptic drop attacks

1 reference

12 December 2020

Neuronal degeneration in canine narcolepsy

1 reference

12 December 2020

Orexin A but not orexin B rapidly enters brain from blood by simple diffusion.

1 reference

12 December 2020

A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy

1 reference

12 December 2020

Control of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsy

1 reference

12 December 2020

Running promotes wakefulness and increases cataplexy in orexin knockout mice

1 reference

12 December 2020

Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy

1 reference

12 December 2020

Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset

1 reference

12 December 2020

Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion

1 reference

12 December 2020

Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs

1 reference

12 December 2020

Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis

1 reference

12 December 2020

Treatment of cataplexy in a three-year-old using venlafaxine

1 reference

12 December 2020